In 2021, operating income from these PBMs' affiliated pharmacies from specialty generics totaled 12% of all operating income for the parent corporations' business segments. The Big 3 PBMs are ...

The agency’s report found that the “Big 3 PBMs” – CVS Health’s (CVS) Caremark Rx, UnitedHealth’s (UNH) OptumRx, and Cigna’s (CI) Express Scripts – marked up “numerous specialty ...

Discover how the three largest pharmacy benefit managers are rejecting biosimilars from their formularies, except for their own private-label drugs.

The "Big 3" PBMs also separately generated an estimated $1.4 billion of income from spread pricing, FTC finds. Jeff Lagasse, Editor A complete guide to lease accounting for healthcare organizations ...

The report found that these “Big 3” pharmacy benefit managers (PBMs) in the U.S. pocketed about $7.3 billion in excess revenue between 2017 and 2022 by marking up certain medicines by ...

Staff’s latest report found that the ‘Big 3 PBMs’—Caremark Rx, LLC (CVS), Express Scripts, Inc. (ESI), and OptumRx, Inc. (OptumRx)—marked up numerous specialty generic drugs dispensed at ...

Pharmacy benefit managers overcharged for specialty generic medications — in many cases by hundreds and thousands of percent ...

In fact, a recent report found that 52% of employers are considering changing their PBM in the next 1-3 years. While 72% of employers still primarily contract with a Big Three PBM, 12% have ...

During the study period, the affiliated pharmacies of the Big Three PBMs earned more than $7.3 billion in dispensing revenue above their estimated acquisition cost, as determined by the National ...

The three biggest PBM-owned pharmacies charged ... The new report is a sequel to a report, released in July, that accused big PBMs of paying their own pharmacies more for drugs than they paid ...

The investigation revealed the three biggest PBMs undertook a variety of actions that boosted their earnings but increased costs for plan sponsors, taxpayers and patients, according to the FTC.